Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
66.95
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
3 Dividend Stocks to Buy Hand Over Fist in March
March 10, 2024
Income investors might want to load up on these great dividend stocks.
Via
The Motley Fool
The AI Race Gets Litigious
March 09, 2024
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Exposures
Artificial Intelligence
Intellectual Property
FDA Conditionally Approves Expanded Use Of BeiGene's Combination Drug For Certain Type Of Blood Cancer
March 08, 2024
FDA grants accelerated approval to BeiGene's Brukinsa for relapsed/refractory follicular lymphoma. Approved in combination with Roche's Gazyva after two or more lines of therapy. Brukinsa, priced at...
Via
Benzinga
Exposures
Product Safety
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales.
Via
Benzinga
Balancing Dividends and Fundamentals: The Case of NASDAQ:GILD.
March 05, 2024
Exploring GILEAD SCIENCES INC (NASDAQ:GILD)'s dividend characteristics.
Via
Chartmill
$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today
February 23, 2024
Via
Benzinga
Is NASDAQ:GILD a Good Fit for Dividend Investing?
February 12, 2024
Analyzing GILEAD SCIENCES INC (NASDAQ:GILD)'s Dividend Potential.
Via
Chartmill
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
March 06, 2024
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.
Via
Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
Hidden Gems: 7 Oversold Stocks Ready for a Major Rebound
March 04, 2024
While red ink signals danger, for these oversold stocks ready for rebound, they could imply upside opportunities.
Via
InvestorPlace
Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges
March 04, 2024
The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio’s market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody...
Via
Talk Markets
3 Dividend Stocks That Are No-Brainer Buys Right Now
February 24, 2024
These stocks check off multiple boxes for investors.
Via
The Motley Fool
History Says the Nasdaq Will Keep Soaring in 2024 -- and Wall Street Thinks This High-Yield Dividend Stock Could Jump Nearly 20%
February 24, 2024
This biotech stock could be poised for a nice rebound if analysts are right.
Via
The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
Stock Alert: 3 Market Giants on the Brink of Monumental Rallies
February 20, 2024
These are the stocks to buy to unlock the secrets of market giants in various industries for monumental growth and returns.
Via
InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.
Via
InvestorPlace
Why Is Gilead Sciences Stock Trading Lower Today?
February 16, 2024
Gilead Sciences' global enrollment pause in magrolimab solid tumor studies. FDA issues partial clinical hold. Explore the impact on ongoing trials.
Via
Benzinga
Exposures
Product Safety
When you look at NASDAQ:GILD, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
February 16, 2024
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
February 14, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
CymaBay Therapeutics Deal May Not Be Needle Moving For $100B Valued Gilead, But Acquisition Is Reasonably Priced: Analyst
February 13, 2024
Gilead's acquisition of CymaBay Therapeutics for $4.3 billion strengthens its liver disease portfolio. Analysts see potential in seladelpar's impact on PBC and pruritus, projecting peak sales of $800...
Via
Benzinga
Dow Surges Over 150 Points; Gilead Sciences To Acquire CymaBay Therapeutics For $4.3B
February 12, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Monday. The Dow traded up 0.48% to 38,856.99 while the NASDAQ rose 0.26% to 16,031.87. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why is CymaBay (CBAY) Stock Up 25% Today?
February 12, 2024
CymaBay stock is rising higher on Monday as CBAY investors react to a $4.3 billion acquisition deal with Gilead Sciences.
Via
InvestorPlace
Health Care Company Gilead Sciences Announces Acquisition of CymaBay Therapeutics
February 12, 2024
Via
Benzinga
Drugmaker Gilead Sciences Scoops Up Liver-Disease Focused CymaBay Therapeutics For $4.3B
February 12, 2024
Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, advancing liver disease treatment with seladelpar. FDA priority review was granted, and there is potential for significant revenue...
Via
Benzinga
Exposures
Product Safety
CymaBay Stock Rockets After Gilead Sciences Unveils $4.3 Billion Acquisition
February 12, 2024
The company is working on a treatment for primary biliary cholangitis, a liver disease treatment.
Via
Investor's Business Daily
Gilead Sciences Stock Approaches Daily Buying Area
February 12, 2024
Gilead Sciences, Inc. is an US American biopharmaceutical company. It focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and...
Via
Talk Markets
Exposures
COVID-19
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
February 11, 2024
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
Top 5 Health Care Stocks That Are Preparing To Pump In February
February 09, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
29
30
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.